ADIM
STOK icon

Alpha DNA Investment Management’s Stoke Therapeutics STOK Stock Holding History

Alpha DNA Investment Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-73
Closed -$2K – 574
2021
Q1 		$2K Buy
+73
New +$4.16K ﹤0.01% 585

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Alpha DNA Investment Management's STOK Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Stoke Therapeutics (STOK) in Q2 2021, closing a stake of 73 shares — an estimated $2K sold.

Alpha DNA Investment Management first reported a position in STOK in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 97 funds tracked by Wall St. Rank hold STOK as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Stoke Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 73 Stoke Therapeutics shares in Q2 2021, an estimated $2K.
  • Alpha DNA Investment Management first reported a position in Stoke Therapeutics in Q1 2021 and held it in 1 quarter.
  • Alpha DNA Investment Management's Stoke Therapeutics position peaked at $2K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.